Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The healthcare giant has been a fairly stable investment this year, but does it belong in your portfolio for the long term?

Is Johnson & Johnson a Buy?

McDonald's

Old Republic International

Many older Americans are more scared about outliving their wealth than death itself. Accordingly, the search for dividend stocks to buy for retirement is one that many take seriously.

The 3 Best Dividend Stocks to Buy for Retirement

Chevron

Coca-Cola

Kroger

Mondelez

Procter & Gamble

If any investor has stood the test of time, it is Warren Buffett. For years, the “Oracle of Omaha” has had a rock-star-like presence in the investing world.

6 of Warren Buffett's Top Stocks Are Very Safe Q4 Buys With Big, Dependable Dividends

The factors keeping ARK Invest's boss away might actually be reasons to buy, depending on your needs.

3 Reasons Why Cathie Wood Won't Touch This Warren Buffett Stock

Johnson & Johnson named its consumer business Kenvue on Wednesday, moving ahead with its plans to spin-off the unit in what would be the biggest shake-up in the healthcare conglomerate's 135-year history.

J&J names consumer health business Kenvue ahead of spin-off

Johnson & Johnson JNJ, -0.46% unveiled Wednesday the name for its New Consumer Health Company that is being spun off: Kenvue. The name, pronounced ken-view, comes from the English word "ken," which is primarily used on Scotland and means knowledge, and "vue," which references sight.

J&J to name its consumer health company 'Kenvue' after spin off

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the “Company”) (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland,

Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company

DUBAI--(BUSINESS WIRE)--Raghu Krishnan Named Johnson & Johnson's New Consumer Health  Area Managing Director for Africa, Middle East, and Turkey

Raghu Krishnan Named Johnson & Johnson's New Consumer Health Area Managing Director for Africa, Middle East, and Turkey

Cardinal Health

Enphase Energy

We're in the midst of a bear market. That's something investors haven't seen in quite some time.

3 Blue-Chip Stocks to Buy to Tap Into a Hidden Bull Market

Boeing

Dow Inc

Goldman Sachs

Visa

Verizon

It's a bear market, and virtually all stocks are trending downward. But some are holding up better than others, and the Dow Jones Industrial Index stocks are one of the stronger groups.

7 Dow Stocks to Buy to Tap Into a Hidden Bull Market

Home Depot

Realty Income Corp

As we near the end of the third quarter, the U.S. stock market is approaching new lows. As volatility increases, investors are becoming more emotional as many portfolios continue to rack up losses.

3 Dividend Stocks to Buy Before the Bull Market Returns

Apple

Amgen

Caterpillar

Celsius Holdings

Clearfield

Fusion Pharmaceuticals

Intrepid Potash

JPMorgan Chase & Co

Larimar Therapeutics Inc

Merck

Microsoft

TravelCenters of America

Tidewater

Viridian Therapeutics

Wave Life Sciences

Two new Breakout Stocks for Week 39 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +108.7% YTD. This week no picks beat 10% gains in less than a week with SLCR peak at +7.1% and continuing the highest negative Momentum Gauges® warning levels since July.

MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An Edge

Domino's Pizza

Sherwin-Williams

These 4 stocks showed strength on a day when most other stocks showed weakness.

4 Major Stocks That Stayed Positive During Friday's Stock Market Crash

American Express

2 top dow jones industrial average stocks to check out this week.

Best Stocks To Buy Now? 2 Dow Jones Stocks To Watch This Week

Blue-chip stocks such as Johnson & Johnson continue to hold up much better than most stocks.

Why Johnson & Johnson Stock Defied the Market Downturn Today

CF Industries Holdings

Canadian Natural Resources

Cenovus Energy

Marcus & Millichap

Novartis

Sociedad Quimica Y Minera De Chile

Investors who have a high exposure to stocks in 2022 probably wish the year would end. Unless they raised their allocation in cash, their losses in the portfolio are mounting.

7 Safe Havens All Investors Should Have Exposure to in 2022

Johnson & Johnson is in a great sector for a recession. The company has grown 16.5% a year for the past ten years.

Johnson & Johnson: A Defensive Recession Play For A Rocky Economy

With the U.S. economy staring at another recession, it may be a good time to lean on the stability and income of the dividend growth champs.

3 Defensive Stocks With 60-Year Dividend Hike Streaks

"When it comes to developing new medicines, our ability to process hundreds of millions of data points makes us much smarter and faster," Duato said.

News for Johnson & Johnson Stock (JNJ)